Importantly, many studies have demonstrated that increased TOP2A expression is correlated with improved prognosis in GBM, measured as survival at 2 years (51), 5-year progression free survival and overall survival (52, 53) (correlative evidence). Here, TOP2A is linked to glioblastoma.